Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience

Yuan Yuan; Susan E. Yost; John Yim; Yate-Ching Yuan; Nicola M. Solomon; Isa Mambetsariev; Sumanta Pal; Paul Frankel; Ravi Salgia; Susan L. Neuhausen; Joanne Mortimer

doi:10.18632/oncotarget.20632

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience

PDF | How to cite

Oncotarget. 2017; 8:62817-62817. https://doi.org/10.18632/oncotarget.20632

Metrics: PDF 2089 views | ?

Yuan Yuan¹, Susan E. Yost¹, John Yim³, Yate-Ching Yuan², Nicola M. Solomon¹, Isa Mambetsariev¹, Sumanta Pal¹, Paul Frankel⁴, Ravi Salgia¹, Susan L. Neuhausen⁵, Joanne Mortimer¹

¹ Department of Medical Oncology & Molecular Therapeutics, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA
² Bioinformatics Core Facility, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA
³ Department of Surgery, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA
⁴ Department of Biostatistics, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA
⁵ Department of Population Sciences, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA

Published: September 05, 2017

This article has been corrected: Dr. John Yim was added to the author list. The authors sincerely apologize for this oversight.

Original article: Oncotarget. 2017;8:26414-23. DOI:https://doi.org/10.18632/oncotarget.14476.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20632

Publication Alerts

Corrections:

Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience